- Home
- GGT vs ACRS Comparison
GGT vs ACRS Comparison
Compare GGT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGT
- ACRS
- Stock Information
- Founded
- GGT 1994
- ACRS 2012
- Country
- GGT United States
- ACRS United States
- Employees
- GGT N/A
- ACRS N/A
- Industry
- GGT Trusts Except Educational Religious and Charitable
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- GGT Finance
- ACRS Health Care
- Exchange
- GGT Nasdaq
- ACRS Nasdaq
- Market Cap
- GGT 136.5M
- ACRS 132.0M
- IPO Year
- GGT N/A
- ACRS 2015
- Fundamental
- Price
- GGT $4.86
- ACRS $2.72
- Analyst Decision
- GGT
- ACRS Strong Buy
- Analyst Count
- GGT 0
- ACRS 5
- Target Price
- GGT N/A
- ACRS $8.75
- AVG Volume (30 Days)
- GGT 59.7K
- ACRS 1.1M
- Earning Date
- GGT 01-01-0001
- ACRS 11-06-2024
- Dividend Yield
- GGT 15.56%
- ACRS N/A
- EPS Growth
- GGT N/A
- ACRS N/A
- EPS
- GGT 0.83
- ACRS N/A
- Revenue
- GGT N/A
- ACRS $27,079,000.00
- Revenue This Year
- GGT N/A
- ACRS N/A
- Revenue Next Year
- GGT N/A
- ACRS N/A
- P/E Ratio
- GGT $6.90
- ACRS N/A
- Revenue Growth
- GGT N/A
- ACRS 26.35
- 52 Week Low
- GGT $4.32
- ACRS $0.86
- 52 Week High
- GGT $7.00
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- GGT 49.92
- ACRS 41.17
- Support Level
- GGT $4.61
- ACRS $2.91
- Resistance Level
- GGT $5.12
- ACRS $3.29
- Average True Range (ATR)
- GGT 0.08
- ACRS 0.29
- MACD
- GGT -0.04
- ACRS -0.18
- Stochastic Oscillator
- GGT 48.08
- ACRS 0.75
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.